• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Announces Launch of ZanthoSyn™ in Hawaii GNC Stores

Jan 25, 2017

Cardax Appoints Global Healthcare Executive as Independent Director

Jan 10, 2017

Cardax Reports Successful Launch of ZanthoSyn™

Nov 14, 2016

Cardax Launches First Product ZanthoSyn™

Aug 24, 2016

Cardax Enters Into Equity Purchase Agreement for Financing of Up to $5 Million

Jul 18, 2016

Cardax Awarded U.S. Inflammation Patent

Nov 17, 2015

Cardax to Lead Aging Discussion at Chaminade University

Oct 6, 2015

Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study

Jul 29, 2015

Cardax Raises Additional $500,000 in Financing

Jun 30, 2015

Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin

Jun 18, 2015
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded StudyDecember 6, 2023
    • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
    • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021

    *These statements have not been evaluated by the Food and Drug Administration.
    This product is not intended to diagnose, treat, cure, or prevent any disease.

    © 2025 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

    • About Us
      • Corporate Overview
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • ZanthoSyn®
      • CDX-101
      • CDX-301
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe